Expression of estrogen receptors in non-malignant mammary tissue modifies the association between insulin-like growth factor 1 and breast cancer risk.
Expression of estrogen receptors in non-malignant mammary tissue modifies the association between insulin-like growth factor 1 and breast cancer risk.
复制标题
非恶性乳腺组织中雌激素受体的表达改变了胰岛素样生长因子 1 与乳腺癌风险之间的关联。
DOI：
10.1093/annonc/mdu583
复制
发表时间：
2015
期刊：
影响因子：
--
通讯作者：
Lagiou,P
中科院分区：
文献类型：
--
作者：
Samoli,E;Lagiou,A;Zourna,P;Barbouni,A;Georgila,C;Tsikkinis,A;Vassilarou,D;Minaki,P;Sfikas,C;Spanos,E;Trichopoulos,D;Lagiou,P
我们已经发现证据支持胰岛素样生长因子-1与雌激素受体α(ERα)在非恶性乳腺组织中的表达在乳腺癌发病机制中的相互作用。多项研究表明，胰岛素样生长因子1(IGF-1)与雌激素受体阳性[ER(+)]乳腺癌的风险呈正相关，而与ER(-)乳腺癌的相关性很小或没有关联。在希腊雅典进行的病例对照调查中，我们研究了102名ERα(+)乳腺癌患者，并将她们的血IGF1水平与178名ERα(+)和83名ERα(-)良性乳腺疾病(BBD)患者的血液水平进行了比较。结果ERα(+)乳腺癌患者的胰岛素样生长因子-1水平明显高于女性乳腺癌患者[优势比(OR)1.36，95%可信区间(CI)：0.95~1.94，每1个标准差(SD)增加]。当考虑到女性BBD患者的ERα状态时，ERα(+)乳腺癌患者与ERα(+)BBD患者之间IGF1水平的差异明显是由ERα(+)患者与ERα(+)BBD患者之间的差异驱动的(OR=1.95，95%CI：1.31~2.89每1个SD的IGF1水平增加)，而当ER IGF(+)乳腺癌患者与ER IGF(-)BBD患者进行比较时，IGF1水平基本上没有相关性。这些对比在绝经后/围绝经期妇女中尤其明显。结论(S)我们发现了在乳腺癌发病机制中IGF1与ERα在非恶性乳腺组织中的相互作用的证据。这与之前的证据一致，该证据表明IGF-1会增加ER(+)乳腺癌的风险。
We have found evidence in support of an interaction of IGF-1 with the expression of estrogen receptor α (ERα) in the non-malignant mammary tissue in the context of breast cancer pathogenesis. This is in line with previous evidence suggesting that IGF-1 increases the risk of ER(+) breast cancer.BackgroundSeveral studies have reported that the insulin-like growth factor 1 (IGF-1) is positively associated with estrogen receptor-positive [ER(+)] breast cancer risk, whereas there is little or no association with respect to ER(-) breast cancer. All comparisons of ER(+) breast cancer cases, however, have been made versus healthy controls, for whom there is no information about the ER expression in their mammary gland.Patients and methodsIn the context of a case–control investigation conducted in Athens, Greece, we studied 102 women with incident ERα(+) breast cancer and compared their IGF-1 blood levels with those of 178 ERα(+) and 83 ERα(-) women with benign breast disease (BBD) who underwent biopsies in the context of their standard medical care. Data were analysed using multiple logistic regression and controlling for potential confounding variables.ResultsERα(+) breast cancer patients had higher IGF-1 levels compared with women with BBD [odds ratio (OR) 1.36, 95% confidence interval (CI): 0.95–1.94, per 1 standard deviation (SD) increase in IGF-1 levels]. When ERα status of women with BBD was taken into account, the difference in IGF-1 levels between ERα(+) breast cancer patients and women with BBD was clearly driven by the comparison with BBD women who were ERα(+) (OR = 1.95, 95% CI: 1.31–2.89 per 1 SD increase in IGF-1 levels), whereas there was essentially no association with IGF-1 levels when ERα(+) breast cancer patients were compared with ERα(-) BBD women. These contrasts were particularly evident among post/peri-menopausal women.Conclusion(s)We found evidence in support of an interaction of IGF-1 with the expression of ERα in the non-malignant mammary tissue in the context of breast cancer pathogenesis. This is in line with previous evidence suggesting that IGF-1 increases the risk of ER(+) breast cancer.